The CQDM is pleased to highlight the recent achievements of one of its members, Glycovax Pharma, a Montreal-based biopharmaceutical company specializing in glyco-immunology and the development of semi-synthetic vaccines.
On one hand, Glycovax is launching large-scale production of the SLA vaccine adjuvant, an innovative compound developed by the National Research Council of Canada (NRC), which has demonstrated exceptional ability to enhance immune response and improve the effectiveness of both existing and next-generation vaccines.
👉 Read the press release: Glycovax Pharma launches a highly performant SLA Adjuvant – Glycovax Pharma
On the other hand, the company has obtained an exclusive license from the NRC to develop a vaccine against Pseudomonas aeruginosa, an antibiotic-resistant hospital-acquired bacterium identified by the WHO as a priority target.
👉 Read the press release: Pseudomonas aeruginosa Vaccine | Glycovax Granted NRC Licence
These breakthroughs confirm Glycovax’s leading role in developing innovative vaccine solutions to address urgent global medical needs.
Learn more about Glycovax Pharma: Glycovax – Advancing Next-Generation Conjugate Vaccines
